208 related articles for article (PubMed ID: 36053834)
1. ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.
Akhoundova D; Hussung S; Sivakumar S; Töpfer A; Rechsteiner M; Kahraman A; Arnold F; Angst F; Britschgi C; Zoche M; Moch H; Weber A; Sokol E; Fritsch RM
Int J Cancer; 2022 Dec; 151(12):2161-2171. PubMed ID: 36053834
[TBL] [Abstract][Full Text] [Related]
2. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
3. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
4.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract][Full Text] [Related]
5. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
6. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
[TBL] [Abstract][Full Text] [Related]
9. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Dong D; Shen G; Da Y; Zhou M; Yang G; Yuan M; Chen R
Oncologist; 2020 Nov; 25(11):e1720-e1724. PubMed ID: 32652753
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract][Full Text] [Related]
12. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
13. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
14. Deepening the Knowledge of
Guaitoli G; Bertolini F; Bettelli S; Manfredini S; Maur M; Trudu L; Aramini B; Masciale V; Grisendi G; Dominici M; Barbieri F
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884672
[No Abstract] [Full Text] [Related]
15. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract][Full Text] [Related]
17. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.
Ren S; Huang S; Ye X; Feng L; Lu Y; Zhou C; Zhao J; He T; Wang J; Li B
Cancer Treat Res Commun; 2021; 27():100377. PubMed ID: 33945921
[TBL] [Abstract][Full Text] [Related]
19. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
20. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]